|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.16 INR | +6.11% |
|
+11.59% | +22.13% |
| Market Cap | 18.52B 195M 168M 155M 145M 272M 276M 1.83B 714M 9.01B 731M 716M 31.21B | P/E Ratio 2024 |
22.4x | P/E Ratio 2025 | 21.8x |
|---|---|---|---|---|---|
| Enterprise Value | 18.52B 195M 168M 155M 145M 272M 276M 1.83B 714M 9.01B 731M 716M 31.21B | EV / Sales 2024 |
1.27x | EV / Sales 2025 | 1.45x |
| Free-Float |
57.31% | Yield 2024 * |
-
| Yield 2025 | 0.42% |
Last Transcript: Morepen Laboratories Limited
| 1 day | +6.11% | ||
| 1 week | +11.59% | ||
| Current month | +15.82% | ||
| 1 month | +9.69% | ||
| 3 months | +25.09% | ||
| 6 months | +21.10% | ||
| Current year | +22.13% |
| 1 week | 42.52 |  | 51.8 |
| 1 month | 39.9 | | 51.8 |
| Current year | 33.44 | | 51.8 |
| 1 year | 33.44 | | 66.36 |
| 3 years | 27.08 | | 100.8 |
| 5 years | 23.65 | | 100.8 |
| 10 years | 7.21 | | 100.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sushil Suri
CEO | Chief Executive Officer | 62 | 1992-01-31 |
| Director of Finance/CFO | 59 | 2002-04-02 | |
| Compliance Officer | 40 | 2018-11-11 |
| Director | Title | Age | Since |
|---|---|---|---|
Sushil Suri
CHM | Chairman | 62 | 1992-01-31 |
Sanjay Suri
BRD | Director/Board Member | 57 | 2019-08-12 |
| Director/Board Member | 57 | 2019-08-12 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.11% | +11.59% | -25.56% | +85.50% | 271M | |
| -2.04% | +0.62% | +40.19% | +155.64% | 1,035B | |
| +0.95% | +3.42% | +53.67% | +50.56% | 574B | |
| +0.88% | +0.10% | +18.21% | +65.15% | 397B | |
| +0.58% | +0.77% | +21.19% | +15.95% | 324B | |
| -0.85% | -2.86% | +22.05% | +13.80% | 281B | |
| +0.44% | +3.48% | +24.48% | +34.39% | 278B | |
| +1.66% | +5.61% | -44.67% | -47.49% | 193B | |
| -0.01% | +1.14% | +18.93% | +62.67% | 191B | |
| -0.21% | -2.93% | +11.90% | +61.03% | 156B | |
| Average | +0.78% | +2.03% | +14.04% | +49.72% | 343.02B | |
| Weighted average by Cap. | -0.22% | +2.39% | +28.09% | +72.00% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 17.02B 179M 155M 143M 133M 250M 254M 1.68B 656M 8.28B 672M 658M 28.68B | 18.12B 191M 165M 152M 142M 266M 270M 1.79B 698M 8.82B 715M 700M 30.53B |
| Net income | 962M 10.12M 8.74M 8.05M 7.54M 14.12M 14.34M 95.07M 37.07M 468M 37.97M 37.16M 1.62B | 1.18B 12.42M 10.72M 9.88M 9.25M 17.34M 17.6M 117M 45.5M 574M 46.6M 45.61M 1.99B |
| Net Debt | 121M 1.27M 1.1M 1.01M 945K 1.77M 1.8M 11.92M 4.65M 58.67M 4.76M 4.66M 203M | -928K -9.76K -8.43K -7.77K -7.27K -13.63K -13.84K -91.75K -35.77K -452K -36.64K -35.86K -1.56M |
Employees
1,814
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 50.16 ₹ | +6.11% | 816,998 |
| 26-06-11 | 47.27 ₹ | -4.25% | 707,246 |
| 26-06-10 | 49.37 ₹ | +1.50% | 2,181,408 |
| 26-06-09 | 48.64 ₹ | +13.62% | 1,773,568 |
| 26-06-08 | 42.81 ₹ | -2.22% | 218,386 |
- Stock Market
- Stocks
- 500288 Stock
Select your edition
All financial news and data tailored to specific country editions
